We have previously observed that compounds that inhibit the activity of C/EBPβ, but not of MYB, also down-regulate the expression of many MYB target genes and exert similar biological effects in AML cells as MYB inhibitors [45]. This evidence concerns the gene MYB and acute myeloid leukemia.